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Abstract
Identification of common molecular pathways affected by genetic variation in autism is important for understanding
disease pathogenesis and devising effective therapies. Here, we test the hypothesis that rare genetic variation in the
metabotropic glutamate-receptor (mGluR) signaling pathway contributes to autism susceptibility. Single-nucleotide variants
in genes encoding components of the mGluR signaling pathway were identified by high-throughput multiplex sequencing
of pooled samples from 290 non-syndromic autism cases and 300 ethnically matched controls on two independent next-
generation platforms. This analysis revealed significant enrichment of rare functional variants in the mGluR pathway in
autism cases. Higher burdens of rare, potentially deleterious variants were identified in autism cases for three pathway
genes previously implicated in syndromic autism spectrum disorder, TSC1, TSC2, and SHANK3, suggesting that genetic
variation in these genes also contributes to risk for non-syndromic autism. In addition, our analysis identified HOMER1,
which encodes a postsynaptic density-localized scaffolding protein that interacts with Shank3 to regulate mGluR activity, as
a novel autism-risk gene. Rare, potentially deleterious HOMER1 variants identified uniquely in the autism population
affected functionally important protein regions or regulatory sequences and co-segregated closely with autism among
children of affected families. We also identified rare ASD-associated coding variants predicted to have damaging effects on
components of the Ras/MAPK cascade. Collectively, these findings suggest that altered signaling downstream of mGluRs
contributes to the pathogenesis of non-syndromic autism.
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Introduction
Autism is a brain disorder of early childhood characterized by
impaired communication, impaired social interaction and restrict-
ed and repetitive patterns of activities and interests. The
phenotypic breadth of autism is encompassed by the term autism
spectrum disorder (ASD), which collectively affects nearly 1% of
children, typically with onset prior to the age of three years.
Insights into the genetic landscape of ASDs have indicated
substantial heterogeneity. Identification of the genes responsible
for recognized neurogenetic syndromes with high prevalence of
ASD, such as FMR1 and TSC1/2, and localization of causative
genes within microdeletions associated with non-syndromic
(idiopathic) autism, such as SHANK3, NLGN3, and NLGN4, have
highlighted the role of single-gene mutations in disease pathogen-
esis (reviewed in [1–4]). A series of recent genome-wide studies
have revealed a significant contribution of rare de novo copy
number variants (CNVs) affecting many different loci to ASD
susceptibility [5–9]. These known genetic factors are estimated to
account for less than 20% of ASD cases, however, and thus much
of the genetic basis of ASDs remains unexplained.
Identification of common molecular pathways affected by
genetic variation in autism is essential to understand disease
pathophysiology and devise effective therapeutic strategies [10].
Increasing evidence suggests a central role for defects in synaptic
structure and function in the pathogenesis of autism despite the
underlying genetic heterogeneity [3,11–14]. However, the neuro-
nal pathways subserving synapse structure and function which are
pathologically altered and which may represent convergence
points for genetic lesions in autism remain to be defined. In this
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35003study, we tested the hypothesis that functional genetic variation in
components of the signaling network coupling group 1 mGluRs to
synaptic protein synthesis contributes to the pathogenesis of non-
syndromic autism. Several lines of evidence suggest that the
‘‘mGluR pathway’’ may play an important role in ASD
pathophysiology [4]. Group 1 mGluRs (mGluR1/5) signal
through the Ras/ERK and PI3K/mTOR signaling cascades to
regulate protein synthesis (Fig. 1). Syndromic disorders with high
prevalence of ASD are caused by mutations in pathway
components that regulate ERK activity (NF1, RAS isoforms, RAF
isoforms, MAP2K1, MAP2K2), mTOR activity (TSC1, TSC2,
PTEN) or mRNA translation directly (FMR1) [4]. Analysis of
Fmr1
2/Y mice, a model of fragile X syndrome, the most common
inherited cause of autism, has revealed excessive mGluR5-
dependent synaptic protein synthesis and plasticity [15]. An array
of phenotypes in these mice could be corrected by attenuation of
mGluR5 activity [16]. Similarly, analysis of Nf1
2/2 and Tsc2
+/2
mice has suggested treatments to correct behavioral impairment in
neurofibromatosis and tuberous sclerosis complex (TSC) [17,18].
Thus, understanding how genetic variation in the mGluR pathway
contributes to non-syndromic autism may suggest new therapeutic
interventions since this pathway is amenable to pharmacological
manipulation.
To test the hypothesis that genetic variation in the mGluR
pathway increases risk for non-syndromic autism, we took
advantage of the massively parallel sequencing capacity offered
by next-generation sequencing (NGS) technologies to interrogate a
panel of candidate genes in a cohort of autism cases and controls.
Our strategy was designed to enhance high-throughput discovery
by performing variant discovery in pools of samples (Fig. 2A). We
then resequenced ‘‘orthogonal’’ pools on a second next-generation
platform to validate variants and assign them to individual
samples. We applied this approach to identify variants associated
with autism in coding exons or flanking sequences in a panel of 18
genes encoding key components of the mGluR pathway [4] (Fig. 1;
Table S1). Genes selected for analysis encode group 1 mGluRs
(mGluR1, mGluR5), postsynaptic density (PSD)-associated scaf-
folding proteins that regulate mGluR function (Homer1, Shank3),
components of the Ras/ERK (H-Ras, Raf, MEK1, MEK2) and
PI3K/mTOR (PI3K catalytic and regulatory subunits, PTEN,
TSC1, TSC2, Rheb) signaling cascades, mRNA-binding factors
that regulate protein synthesis (eIF4E, FMRP), a protein target of
mGluR-induced translation that regulates synaptic plasticity (Arc),
and an E3 ubiquitin ligase known to regulate Arc degradation
(Ube3a) [19]. Although some of the genes studied are known to
cause syndromic ASD (e.g. FMR1, TSC1, TSC2, UBE3A), their
possible role in non-syndromic autism has been unclear.
Results
We analyzed single-nucleotide variants (SNVs) in mGluR
pathway genes by high-throughput sequencing in a cohort of
290 unrelated AGRE cases and 300 ethnically-matched controls
(Fig. 2A; Table S2). Inclusion criteria for AGRE cases were a
diagnosis of idiopathic (‘‘non-syndromic’’) autism and at least one
affected sibling. AGRE cases are screened to exclude non-
idiopathic (‘‘syndromic’’) autism secondary to known neurogenetic
disorders such as fragile-X syndrome [20]. Two distinct sets of
pools were prepared from genomic DNA samples isolated from
these cohorts for sequencing on the Illumina GAII and the Helicos
HeliScope. An orthogonal strategy for sample pooling was used in
which samples were arrayed in a matrix with 15 rows and 20
columns. Samples were pooled along rows to generate 15 pools of
20 samples each for GAII sequencing and pooled along columns
to generate 20 pools of 15 samples each for Heliscope sequencing.
Each sample representing a single case or control subject was thus
identified by a unique combination of two pools representing its
unique position within this matrix. Each genomic DNA pool was
used as a template for PCR amplification of all coding exons from
our panel of 18 mGluR pathway genes (240 exons comprising a
total of 40,473 bases). PCR amplicons from each genomic DNA
pool were concatenated and sheared to construct libraries for high-
throughput sequencing. The average coverage per exon per pool
was 610 for the GAII and 1,688 for the HeliScope. An average
coverage of $10 per individual was achieved for 87% (GAII) and
97% (HeliScope) of exons across all pools. Sensitivity of variant
Figure 1. The mGluR pathway coupling synaptic activity to
synaptic protein synthesis. The diagram illustrates components and
interactions in the mGluR pathway [4]. Genes encoding proteins
highlighted in yellow were sequenced in this study. Activation of
postsynaptic group 1 mGluRs (mGluR1, mGluR5) stimulates protein
synthesis by signaling through the Ras/ERK and PI3K/mTOR pathways.
Group 1 mGluR function is modulated by interaction with Homer1,
which interacts in turn with Shank3 and links mGluRs to the network of
postsynaptic density-localized proteins. FMRP regulates synaptic
protein synthesis by binding to target mRNAs and repressing their
translation. Arc regulates mGluR-dependent synaptic plasticity, and its
levels are regulated by FMRP-dependent translation and Ube3a-
dependent degradation. The activity of the mGluR pathway is regulated
by several pathway components responsible for syndromic ASDs
(indicated by asterisks), including NF1 (neurofibromatosis type 1), Ras/
ERK cascade members (cardiofaciocutaneous/Noonan syndromes),
PTEN (ASD with microcephaly), TSC1 and TSC2 (tuberous sclerosis
complex), FMRP (fragile X mental retardation syndrome), and Ube3a
(Angelman’s syndrome). Mutations in Shank3, Nrxn1, Nlgn3, and Nlgn4
cause rare non-syndromic ASDs, and structural variants in SynGAP1 and
DLGAP2/SAPAP2 have been associated with autism (indicated by
asterisks) [7,23,43].
doi:10.1371/journal.pone.0035003.g001
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achieved on the GAII in this analysis.
We used confirmation by Sanger sequencing to evaluate the
sensitivity and fidelity of SNV detection on each NGS platform
and on both platforms combined. The false discovery rate for
single variant occurrences (singletons) fell sharply without losing
sensitivity when considering only SNVs detected concordantly on
both platforms (Fig. S1). We therefore limited our subsequent
analysis to SNVs that were concordantly detected on both
platforms.
Common SNVs were defined as those with allele frequencies
$1%, while rare SNVs were defined as having allele frequencies
,1%. The number of common SNVs did not differ between the
AGRE and control groups (Table 1). Rare SNVs were modestly
enriched in AGRE samples compared to controls (302 and 276,
respectively). However, when we excluded rare SNVs that are
either silent or present in both populations, and therefore
presumed to be benign (Fig. 2B), a significant enrichment of
genetic variation was detected in the autism population, with 80
and 49 SNVs in AGRE and control groups, respectively
(P=0.001). When we additionally eliminated SNVs located in 59
UTRs or deep intronic regions, thereby focusing on SNVs with
potentially deleterious effects, there emerged a two-fold enrich-
ment of variants in the autism population, with 58 and 29 SNVs in
the AGRE and control groups, respectively (P=0.0005), occurring
in 49 and 32 individuals, respectively (Table 1, Table 2, Table S3).
The two-fold enrichment of SNVs in the autism population
persisted if we further excluded SNVs characterized as common in
dbSNP (build 132), with 57 and 27 SNVs in the AGRE and
control populations, respectively (P=0.0002).
We applied several commonly used computational tools for
pathogenicity prediction to assess the functional impact of the rare,
potentially deleterious missense variants identified in the AGRE
and control groups. Since the performance and reliability of
methods for pathogenicity prediction varies widely, and their
results typically correlate poorly [21], we compared the predictions
derived from SIFT, PolyPhen2, SNP&GO and MutPred.
Although SIFT did not predict a significant difference between
groups, PolyPhen2, SNP&GO, and MutPred each predicted a 2-
to 3-fold enrichment of damaging missense variants in the AGRE
group. Overall, comparably high proportions of the variants
classified as potentially deleterious in the AGRE and control
groups (68% and 71%, respectively) were predicted to be
functionally damaging by at least one of the four prediction tools,
supporting the notion that disruptive variants within mGluR
pathway components occur at a higher rate in the autism relative
to the control population.
At the level of individual pathway genes, we identified a
significant excess of SNVs in the autism population for the TSC1,
TSC2, SHANK3, and HOMER1 genes (P,0.05). Causal roles for
TSC1 and TSC2 have previously been demonstrated in syndromic
autism. TSC1 or TSC2 mutations can cause TSC, a syndromic
disorder characterized by tumor growth in multiple organs,
including the brain. Although the manifestations of TSC include
ASD in up to 50% of cases [22], our findings additionally
implicate TSC1 and TSC2 as risk genes for non-syndromic autism
independent of their causative role in TSC. Consistent with this
view, the majority of the rare, potentially disruptive TSC1/TSC2
SNVs identified in the AGRE population are novel, and none of
these SNVs has been identified previously as a cause of TSC
Figure 2. SNV detection and classification. (A) The flow diagram depicts the experimental strategy for SNV discovery and confirmation. For the
AGRE and control cohorts, orthogonal multiplexing was performed to prepare two distinct sets of sample pools (15 pools of 20 samples each, or 20
pools of 15 samples each). Following enrichment of exonic target regions for all 18 mGluR pathway genes, SNVs were identified and confirmed by
deep resequencing of orthogonal pools on two independent NGS platforms (Illumina GAII and the Helicos HeliScope). SNVs concordantly detected
on both platforms were then analyzed as shown in panel B. (B) The flow diagram depicts the procedure used to classify the presumptive functional
effects of identified variants. SNVs concordantly detected on both NGS platforms were classified as common or rare using a minor allele frequency
(maf) threshold of 1%. Common SNVs, rare SNVs occurring in both autism and control populations, and rare synonymous (silent) SNVs were
considered likely to be benign. Rare SNVs in intronic sequences flanking exons that did not affect conserved splice donor or acceptor sites or in 59
untranslated regions were classified as not benign but of unknown significance. Rare SNVs causing missense substitutions or occurring in mRNA 39
untranslated regions (and therefore possibly affecting mRNA stability or translation [28,29]) were considered possibly deleterious, and rare SNVs
causing nonsense mutations or affecting conserved splice donor or acceptor sequences were considered probably deleterious. These latter two
categories of SNVs were together considered potentially deleterious.
doi:10.1371/journal.pone.0035003.g002
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tification of increased genetic variation in SHANK3 in autism cases
supports the emerging view of SHANK3 as an important autism-
risk gene [23]. One missense variant observed in our study
(R300C) was previously identified as a potential risk factor for
ASD [23]. In addition, we identified a number of novel rare
SHANK3 SNVs in the autism population (Table 2). The over-
representation of rare, potentially disruptive variants in genes
previously implicated in ASD (TSC1, TSC2, SHANK3) provides
validation of this approach to detect genes that contribute genetic
risk in autism.
The fourth gene displaying a significant enrichment of autism-
associated rare SNVs, HOMER1, has not previously been
implicated in autism. Homer1 is a PSD-localized scaffolding
protein that interacts with a variety of PSD proteins, including
mGluRs and Shank proteins [24]. Binding of Homer1 to mGluRs
promotes trafficking of mGluRs to the postsynaptic membrane
and couples mGluR5 to the mTOR signaling pathway [25].
Homer and Shank proteins interact to form an extended
polymeric platform required for recruitment and assembly of
synaptic proteins and structural integrity of dendritic spines [26].
Consistent with this function, the Homer-Shank interaction has
been shown to promote morphological and functional maturation
of dendritic spines [27]. We identified multiple rare missense
variants in HOMER1 in AGRE cases but not in controls. All of the
identified missense variants in HOMER1 alter residues that are
invariant among mammalian species, and all but one is invariant
across vertebrate species (Fig. 3A). Two of these variants
(c.195G.T, M65I and c.290C.T, S97L) localize to the EVH1
(Ena/VASP homology 1) domain of Homer1, which binds to Pro-
Pro-Ser-Pro-Phe motifs in mGluR1 and mGluR5 and a Pro-Pro-
Glu-Glu-Phe motif in Shank3 [24]. A third potentially damaging
SNV in HOMER1 (c.425C.T, P142L) affects one of the
conserved prolines within the P-motif of the CRH1 (conserved
region of Homer 1) domain, which serves as an internal binding
site for the EVH1 domain. It has been proposed that the P-motif
competes for binding of the Homer1 EVH1 domain to the proline-
rich motif in target proteins such as mGluRs, thereby modulating
Homer1 homo-multimerization and mGluR interaction. Interest-
ingly, one of the GRM5 variants (c.3503T.C, L1168P) detected in
AGRE samples is located in close proximity to the conserved Pro-
Pro-Ser-Pro-Phe Homer1-binding motif in mGluR5. In addition,
we identified an SNV in the HOMER1 39 UTR (c. 1080 C.T)
only in the autism and not in the control population. Growing
evidence suggests an important role for 39 untranslated regions
(UTRs) as the sites of pathogenic variation due to their diversity
and density of cis-acting regulatory elements [28,29]. In particular,
genetic variants that alter microRNA-binding sites have been
implicated in the pathogenesis of a variety of human diseases,
including the neuropsychiatric disorder Tourette’s syndrome
[30,31]. The identified HOMER1 39 UTR variant, which is
located 15 nucleotides distal to the translation termination codon,
Table 1. Enrichment of rare functional variants in mGluR pathway genes in autism cases detected by high-throughput
sequencing.
Variant Common Rare Rare Rare,
Type: Not benign Not benign
Pot. deleterious
Gene AGRE Ctrl AGRE Ctrl AGRE Ctrl AGRE Ctrl
ARC 2 2 69 31 3 1
EIF4E 1 1 34 10 0 0
FMR1 2 3 37 03 0 2
GRM1 77 2 0 2 5 2 7 2 6
GRM5 22 21 31 29 7 7 3 6
HOMER1 4 4 82 70 50
HRAS 3 3 32 10 1 0
MAP2K1 2 3 54 01 0 1
MAP2K2 56 2 1 1 9 4 1 3 1
PIK3CA 1 61 6 84 22 1 2
PIK3R1 6 6 87 43 1 0
PTEN 1 1 44 00 0 0
RAF1 1 0 78 22 2 2
RHEB 1 1 11 00 0 0
SHANK3 7 6 80 60 19 4 14 3
TSC1 3 5 26 13 11 1 80
TSC2 14 12 61 70 16 15 14 5
UBE3A 2 1 78 12 1 0
All genes 99 98 302 276 80 49 58 29
SNVs in mGluR pathway genes were identified in pools of AGRE or control samples and classified based on allele frequency and predicted functional impact. The values
shown represent the numbers of distinct variants identified. A significant excess of rare, potentially deleterious variants in the AGRE group relative to the control group
was observed for the HOMER1, SHANK3, TSC1,a n dTSC2 genes (highlighted in bold).
doi:10.1371/journal.pone.0035003.t001
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predicted seed pairing for several microRNAs, including miR-96,
miR-182, miR-203, and miR-513a-3p (miRanda and Microcosm
algorithms, www.microrna.org; www.ebi.ac.uk/enright-srv/
microcosm [32,33]) (Fig. 3B). Based on the predicted effects on
microRNA binding, this variant may perturb the efficiency and/or
tissue specificity of HOMER1 mRNA translation and protein
expression.
To assess further the pathogenicity of the rare, potentially
disruptive HOMER1 variants uniquely identified in the autism
population, we analyzed co-segregation of these variants with
autism (Figure 3C). Parents and siblings of probands in the families
carrying each of the five HOMER1 variants were genotyped for the
relevant HOMER1 variant as well as any other rare variants
detected in the proband. Four of the variants (c. 290C.T,
c.425C.T, c. 968G.A, and c.1080 C.T) co-segregated perfectly
with the autism phenotype in affected and unaffected children.
Probands from two of these families carried a second rare variant
in addition to the HOMER1 variant, but these other variants did
not co-segregate with the autism phenotype (HOMER1 c.290C.T
and SHANK3 c.898C.T; HOMER1 c.195 and PIK3CA
c.2294+19C.T). The fifth HOMER1 variant (c.195G.T, the
only HOMER1 variant carried by a female proband) was not
detected in an affected sibling, suggesting that this variant may
modify autism risk. Interestingly, the c.968G.A variant was
present in two affected male children but absent in both parents,
suggesting that this variant arose de novo in one of the parental
germlines. This finding is consistent with increasing evidence that
de novo CNVs and SNVs with high penetrance play major roles in
autism [6,34,35]. The remaining four variants were transmitted to
affected children by unaffected carriers, possibly reflecting
incomplete penetrance of pathogenic variants among parents in
families with multiplex autism [34,36].
Although significant enrichment of rare, potentially disruptive
variants in AGRE samples relative to controls was limited to the
TSC1, TSC2, SHANK3, and HOMER1 genes, individual variants in
additional genes suggest a role for the Ras/ERK cascade in autism
susceptibility. One AGRE sample harbored an SNV in MAP2K2
(c.581-1G.T) that alters a conserved splice-acceptor site; skipping
of the adjoining exon would result in a frameshift mutation within
the kinase domain and is thus highly likely to be damaging.
Familial segregation analysis revealed the presence of this variant
Table 2. Rare, potentially deleterious variants identified in mGluR pathway genes in autism cases.
ARC GRM1 GRM5 HOMER1 HRAS MAP2K2 PIK3CA PIK3R1 RAF1 SHANK3 TSC1 TSC2 UBE3A
c.587C.G c.1882C.G c.727G.T c.195G.T c.383G.A c.581-1G.T c.1544A.G c.889G.A c.122G.A c.612C.A c.346T.G c.433G.A c.333C.G
(P196R) (R628G) (A243S) (M65I) (R128Q) (splice
donor)
(N515S) (E297K) (R41Q) (D204E) (L116V) (A145T) (N111K)
c.605A.T c.2051G.A c.1417G.C c.290C.T c.889C.T c.356C.T c.763C.T c.692C.T c.1292C.T
(D202V) (R684H) (E473Q) (S97L) (R297W) (A119V) (H255Y) (P231L) (A431V)
c.829G.A c.3503T.C c.425C.T c.1217C.T c.898C.T c.1006C.T c.1912G.A
(G277S) (L1168P) (P142L) (39 UTR) (R300C) (R336W) (V638M)
c.968G.A c.920C.G c.1178C.T c.2155T.C
(R323H) (A307G) (T393I) (Y719H)
c.1080C.T c.1315C.T c.1342C.T c.2621C.T
(39 UTR) (P439S) (P448S) (P874L)
c.1337G.T c.1580A.G c.3252C.G
(G446V) (Q527R) (D1084E)
c.3761C.T c.1960C.G c.3827C.T
(A1254V) (Q654E) (S1276F)
c.3764C.T c.2718A.C c.3914C.T
(P1255L) (Q906H) (P1305L)
c.3836C.T c.3974G.A
(P1279L) (G1325D)
c.4025C.T c.4051G.A
(P1342L) (E1351K)
c.4405G.C c.4316G.A
(G1469R) (G1439D)
c.4406G.T c.4460C.G
(G1469V) (S1487C)
c.4490G.A c.5429G.A
(R1497Q) (3’ UTR)
c.4720G.A c.5450G.A
(G1574R) (39 UTR)
Table 2 summarizes the 58 rare, potentially deleterious SNVs that were identified in mGluR pathway genes only in autism cases. For each variant, the nucleotide
substitution is shown, and the corresponding amino acid substitution is indicated parenthetically.
doi:10.1371/journal.pone.0035003.t002
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penetrance. A potentially damaging missense variant was also
detected in HRAS (c.383G.A, R128Q); this substitution alters a
highly conserved basic residue required for interaction of GTP-
bound H-Ras with the plasma membrane and Raf [37]. Familial
segregation analysis revealed absence of this variant in an affected
sibling of the proband, suggesting a modifying rather than causal
role for this variant. Mutations in MAP2K2 and HRAS are
responsible for cardiofaciocutaneous (CFC) and Costello syn-
drome, respectively, related monogenic disorders characterized by
mental retardation, facial dysmorphism, cardiac defects and a high
prevalence of autistic features [38,39]. CFC and Costello
syndromes are thought to be caused by gain-of-function mutations
that activate the Ras/ERK pathway, whereas the MAP2K2 and
HRAS variants that we identified in autism cases are most
compatible with loss of protein function. These findings raise the
possibility that rare genetic variation within the Ras/ERK cascade
may contribute to non-syndromic autism risk independent of this
pathway’s role in CFC and Costello syndromes.
Discussion
The findings reported here lend strong support to the hypothesis
that perturbed function of the signaling pathways coupling
mGluRs to synaptic protein synthesis plays an important role in
autism pathogenesis. Overall, we identified rare, potentially
damaging variants in 20% (58/290) of the autism cases analyzed
but in only 10% (29/300) of controls, suggesting a substantial
contribution of rare functional genetic variation within the mGluR
pathway to autism susceptibility. A series of recent genome-wide
studies has highlighted the association of rare CNVs with autism
[5–9,36,40]. Our findings complement these studies by pointing to
an important role for rare SNVs in pathophysiogically relevant
genes in autism. Consistent with this view, exome sequencing of 20
trios with idiopathic ASD revealed potentially causative de novo
Figure 3. Autism-specific HOMER1 variants affect conserved residues or microRNA binding sites and co-segregate with autism. (A)
Multiple sequence alignments are shown for three segments of the Homer1 protein that contain missense substitutions caused by autism-specific
SNVs identified in this study. The amino acid residues altered by these substitutions (highlighted in red) are highly conserved across mammalian and/
or vertebrate evolution. (B) The autism-specific HOMER1 c.1080C.T variant is predicted to alter multiple microRNA-binding sites in the HOMER1 39
UTR. The sequence of the HOMER1 39 UTR is shown at top (the c.1080 position 15 nucleotides distal to the translation stop codon highlighted in red),
together with a cluster of microRNA binding sites predicted by the miRanda and Microcosm applications (miRanda target prediction based on $ 6-
mer seed complementarity and mirSVR score #0.1) [32,33]. Predicted pairing between specific microRNAs and the HOMER1 39 UTR that would be
altered by the c. 1080 C.T variant is shown at bottom. (C) Co-segregation with autism was analyzed for the rare, potentially deleterious HOMER1
missense variants uniquely identified in AGRE probands by genotyping available parents and siblings. Filled symbols indicate a diagnosis of autism or
ASD; unfilled symbols indicate reportedly unaffected individuals. Genotypes are shown for each individual, with ‘‘+’’ designating the wild-type allele
and ‘‘SNV’’ designating the indicated variant allele.
doi:10.1371/journal.pone.0035003.g003
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intellectual disability and epilepsy [35]. Interestingly, our analysis
revealed a significant excess of rare, potentially deleterious variants
in three known autism genes, SHANK3, TSC1, and TSC2,i n
individuals with non-syndromic autism. Whereas mutations in the
TSC1 and TSC2 genes typically cause syndromic autism in the
context of TSC, our results suggest that these genes contribute to
non-syndromic autism risk independent of their causal role in
TSC. Mutations in SHANK3 have previously been reported as rare
monogenic cause of non-syndromic autism and syndromic autism
(in the context of the 22q13.3 microdeletion syndrome) [23]. A
recent study also identified a number of SNVs in the TSC1, TSC2,
and SHANK3 genes in simplex autism cases (although the
frequency of SNVs in these genes in controls was not reported)
[41]. Taken together, these findings further the view that non-
syndromic and syndromic forms of autism share common
pathophysiological mechanisms.
The identification of HOMER1 as an autism risk gene adds an
important component to the network of PSD proteins causally
implicated in autism, which now includes the products of the
SHANK2 [7,42], SHANK3 [23], NLGN3 [43], NLGN4 [43],
SYNGAP1 [7], and DLGAP2 [7] genes (Fig. 1). A pathogenic role
for HOMER1 variation in autism is supported by several
observations: multiple rare, potentially deleterious variants were
identified in the AGRE population but not in the control
population; these autism-specific HOMER1 missense variants
affect functionally significant protein motifs or regulatory sequenc-
es; these autism-specific variants also display tight co-segregation
with autism in children of affected families, including in one case a
de novo HOMER1 variant present in two affected children. The
Homer1 protein interacts with mGluRs and Shank proteins and
couples mGluR5 to the mTOR signaling pathway [24,25].
Homer1 thus provides a novel link between autism-associated
gene products that operate downstream of mGluRs and those that
interact with Shank proteins, most notably neuroligins [12]. In
addition, the Homer-Shank interaction scaffolds and regulates the
function of group 1 mGluRs, NMDA receptors and AMPA
receptors [24], key glutamate receptor subtypes that mediate
synaptic plasticity. Intriguingly, recent evidence indicates that
disrupted mGluR5-Homer1 interactions in a mouse model of FXS
(Fmr1
-/Y mice) underlies the development of phenotypes relevant
to autism, including hippocampal protein synthesis, neocortical
circuit dysfunction and behavior [44]. The association of rare
functional variation in Homer1 with genetic risk for autism
identified in this study provides further insight into the emerging
role of synaptic dysfunction in autism pathogenesis [3,11–14].
Our identification of rare damaging variants in the HRAS and
MAP2K2 genes further suggests that dysregulation of the Ras/
ERK pathway may contribute to autism risk. Consistent with this
notion, mutations have been identified in SYNGAP1 in both ASDs
and non-syndromic mental retardation [7,45]. SynGAP1, which
interacts with the PSD scaffold through PSD-95, negatively
regulates Ras/ERK pathway activity, synaptic delivery of AMPA
receptors and synaptic transmission [46]. Prior studies have shown
that ERK activation is required for synaptic activity-induced
protein synthesis, mGluR-dependent synaptic plasticity and
cognitive function [47–49].
Collectively, our findings support the view that genetic
susceptibility in autism is attributable to the cumulative contribu-
tion of individually rare variants in components of the signaling
network that couples PSD proteins and downstream effector
mechanisms to synaptic function. Furthermore, our results suggest
that pharmacological modulation of the signaling mechanisms
coupling mGluRs to synaptic protein synthesis may be an effective
therapeutic strategy in autism, and that treatments developed for
syndromic forms of autism may apply more broadly to non-
syndromic autism.
Materials and Methods
Sample selection
Genomic DNA prepared from blood samples was obtained for
all unrelated individuals in the AGRE (Autism Genetic Resource
Exchange) collection [20] who satisfied the diagnostic criteria of
idiopathic (non-syndromic) autism by the Autism Diagnostic
Interview, Revised (ADI-R), and at least one sibling with ASD
(n=290 total). Genomic DNA prepared from blood samples was
obtained from the Coriell collection for healthy control individuals
(n=300). Relevant demographic and diagnostic features of the
AGRE and control cohorts are summarized in Table S2. The sex
ratios in the AGRE and control groups approximate the sex ratios
in the autism and neurotypical populations (4:1 and 1:1,
respectively). Females are less likely than males to express an
ASD phenotype, and pathogenic variants may display decreased
penetrance in female carriers [34,36]. Since we considered
variants detected in both the control and AGRE populations to
be non-pathogenic, over-representation of females in the control
group relative to the AGRE group could lead to undercalling of
variants as pathogenic, but is unlikely to lead to overcalling. We
did not observe any significant differences in the rates of detection
of rare, potentially deleterious variants between males and females
in either the AGRE or control groups (variant rates: AGRE males
19% (44/232), AGRE females 19% (11/58); control males 8.5%
(12/141), control females 7.5% (12/159)). These sex-stratified data
also demonstrate significantly higher rates of rare, potentially
deleterious variants in both AGRE males and AGRE females
relative to their control counterparts. The secondary analysis of
existing, de-identified samples and data from the AGRE and
Coriell repositories conducted in this study was considered exempt
from IRB review.
Next-generation sequencing
DNA concentration was determined for all samples using
Nanodrop (Thermo Fisher Scientific). Equal amounts of control
sample DNAs were combined into orthogonal pools of 20 samples
each and 15 samples each. The same pooling strategy was applied
to the AGRE samples; since only 290 AGRE samples were
available, 10 samples were included in two different 20-sample and
two different 15-sample pools. Each pool then served as the
template for PCR amplification of all coding exons comprising the
longest isoform expressed by each of the 18 candidate genes, using
specific PCR primers tailed at the 59 end with a 14-bp sequence
containing a Not1 restriction site. All PCR products derived from
the same template (i.e. sample pool) were pooled, digested with
Not1, and ligated to form concatemers, which were subsequently
randomly sheared into fragments with a mean size of 150 to
300 bp using a Covaris S2 instrument (Covaris, Woburn, MA).
These fragments were prepared for sequencing on an Illumina
Genome Analyzer II (GAII, Illumina, San Diego, CA) (20-sample
pools) or a Helicos HeliScope (Helicos Biosciences, Cambridge,
MA) (15-sample pools) according to the manufacturers’ instruc-
tions. Illumina sequencing was performed for 50 cycles, resulting
in a read length of ,50 bases, and HeliScope sequencing was
performed for 120 cycles or 30 quads, resulting in an average read
length of 32 bases.
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Reads were aligned to a reference sequence comprising the
hg18-derived sequence of each amplified exon with 30 flanking
intronic (non-coding) bases on each side. The aligner MOSAIK
was used for the GAII reads (https://code.google.com/p/mosaik-
aligner/), and the open source aligner IndexDP for the HeliScope
reads (http://open.helicosbio.com). Variant calling was performed
with GigaBayes for the GAII reads without invoking the Bayesian-
based algorithm (http://bioinformatics.bc.edu/marthlab/
GigaBayes), and with SNPsniffer for the HeliScope reads
(http://open.helicosbio.com). No minimum minor allele frequen-
cy threshold was set in GigaBayes, while in SNPsniffer a minimum
allele frequency of 1% was used because variant calls became
largely unspecific below that threshold. In both cases, variant calls
were only accepted if they occurred at least once on each DNA
strand. No other filters were used during the initial variant calling.
In the subsequent analysis, GAII variant calls were compared to
HeliScope variant calls, and all variants called on both the GAII
(at a frequency of at least 0.5%) and the HeliScope (at a frequency
of at least 1%) were considered confirmed. Confirmed variants
occurring in only one pool on each platform could be assigned to
individual samples, based on the orthogonal construction of the
GAII and HeliScope sample pools. All rare variants discussed in
the text were additionally confirmed by Sanger sequencing.
Sanger sequencing
Sanger sequencing was performed for selected exons in selected
samples to confirm rare variants detected during NGS. PCR
primers and conditions were the same as those used for
amplification of exons from sample pools, except that individual
samples rather than pooled samples served as template. Each PCR
product was then cycle-sequenced using BigDye Terminator v3.1
reagents (Applied Biosystems, Foster City, CA), with the specific
PCR primers serving as sequencing primers, and the sequencing
products were separated on an 3730xl Genetic Analyzer (Applied
Biosystems). Sequencing traces were visualized using Sequence
Scanner software (Applied Biosystems), and presence or absence of
a given mutation determined by manual comparison to the
reference sequence.
Validation of variant confirmation strategy
To determine sensitivity of variant detection and false discovery
rate in pools on the individual sequencing platforms, we
constructed validation pools from 20 (GAII) and 15 (HeliScope)
samples in which Sanger sequencing had previously been
performed on all coding exons of the genes MYBPC3, MHY7,
TNNT2, and TNNI3. Each pool was enriched for these targets by
PCR amplification, and libraries were constructed and sequenced
as described above. The GAII pool contained 17 singleton
substitutions, and the HeliScope pool contained 25 singleton
substitutions. To determine sensitivity and false discovery rate for
the GAII-HeliScope cross-confirmation strategy, we randomly
selected 102 singleton variants detected in only one AGRE or only
one control pool on each platform, which could be assigned to
individual samples based on the unique combination of GAII and
HeliScope pools in which the variant was detected. These samples
were then subjected to Sanger sequencing to test for presence of
the expected variant.
Variant analysis
All variants identified on both the GAII and HeliScope
platforms were classified according to the scheme shown in
Figure 2B. Variants identified on one NGS platform but not on
the other were excluded from the current analysis. Fisher’s exact
test was used to determine the significance of differences in variant
accumulation between AGRE and control populations, with
nominal statistical significance defined as a two-sided P,0.05.
Input values for Fisher’s exact test were calculated from number of
subjects tested and number of distinct potentially deleterious
variants identified, under the simplifying assumptions that each
rare variant occurred only once and no two variants co-occurred.
Comparison with computational predictions of pathogenicity for
missense variants was performed using the SIFT, PolyPhen2,
MutPred and SNPs&GO programs [50–53].
Supporting Information
Figure S1 Receiver-operating characteristic curves for
sensitivity of variant detection and false discovery rate.
The receiver-operating characteristic (ROC) curves show the
sensitivity of detecting singleton variants in 20-sample pools (GAII)
and/or 15-sample pools (HeliScope) as a function of the false
discovery rate (FDR). Each point represents sensitivity and FDR at
a different threshold value for the minimal allowed allele
frequency in the pool. For detection on both platforms, the allele
frequency threshold was varied only for GAII data and kept
constant at 1% for HeliScope data. When allele frequency cut-offs
of 0.5% (GAII) and 1% (HeliScope) were applied to detection on
both platforms, a sensitivity of 99% was achieved for singleton
detection at high coverage with a false discovery rate of 11%,
thereby eliminating most false-positive variants.
(TIF)
Table S1 Components of the mGluR signaling pathway
analyzed in this study. Gene and protein names, cytogenetic
localization and protein function are listed for the 18 genes
encoding mGluR pathway components that were subjected to
next-generation sequencing in a cohort of autism cases and
controls in this study.
(DOC)
Table S2 Cohort demographic and diagnostic charac-
teristics. The demographic and diagnostic features of the AGRE
and control cohorts analyzed in this study are summarized.
(DOCX)
Table S3 Rare variants detected in AGRE and/or
control groups. All SNVs in 18 mGluR pathway genes that
were concordantly detected on both NGS platforms are listed and
annotated in terms of their location and consequence, occurrence
in AGRE and/or control groups, minor allele frequency (maf),
and functional significance as outlined in Fig. 2B.
(PDF)
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